International Journal of Hematology

, Volume 84, Issue 2, pp 158–165 | Cite as

Clinical Evaluation of Recombinant Factor VIII Preparation (Kogenate) in Previously Treated Patients with Hemophilia A: Descriptive Meta-Analysis of Post-Marketing Study Data

  • A. Yoshioka
  • K. Fukutake
  • J. Takamatsu
  • A. Shirahata
  • Kogenate Post-Marketing Surveillance Study Group
Case Report

Abstract

The safety and efficacy of Kogenate, a recombinant factor VIII (rFVIII) preparation for the treatment of bleeding episodes, were studied in a 123-patient meta-analysis population of previously treated patients (PTPs), including 15 enrolled in the registration Phase III trial (PTP-I group), 93 from the post-marketing special investigation (PTP-II group), and 15 from short-term special investigations in surgery or tooth extraction (SI group). These patients (82 severe, 31 moderate, 9 mild, and 1 unknown), aged 11 months to 72 years, were enrolled in 28 centers in Japan. Blood samples taken at the baseline and at 3, 6, 9, 12, 18, and 24 months after the introduction of Kogenate were evaluated for FVIII inhibitor antibodies, antibodies formed against trace proteins derived from the rFVIII production process, and for general changes in laboratory test results. Mean exposure to Kogenate was 1103 days in PTP-I, 86 days in PTP-II, 27 days in patients in surgery, and 2 days in patients with tooth extraction.

Assessment of FVIII inhibitor activity was conducted in 115 of the 123 patients by means of the Bethesda assay. Twelve patients were found to have a low titer of FVIII inhibitor (0.5–3.0 BU/mL) prior to any administration of Kogenate, and 103 were inhibitor-negative at the baseline. Among this latter group, 3 patients (2.9%) tested inhibitor-positive, with titers ranging from 1.2 to 2.1 BU/mL, with 4 patients below 1.0 BU/mL. One patient in the 11 PTPs investigated (PTP-I) developed antibodies against baby hamster kidney protein and mouse immunoglobulin G, but these findings were transient and asymptomatic. Hemostasis was achieved (markedly effective or effective) in 3666 of the 3855 bleeding episodes (95.1%) observed in 108 patients. Only 1 infusion was necessary in 3790 (98.3%) of these episodes. These data indicate that Kogenate is safe and very effective for the treatment of bleeding in PTPs with hemophilia A.

Key words

Hemophilia A Previously treated patients Tooth extraction Operation Recombinant factor VIII (Kogenate) 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. Nature. 1984;312:326–330.CrossRefPubMedGoogle Scholar
  2. 2.
    Wood WI, Capon DJ, Simonsen CC, et al. Expression of active human factor VIII from recombinant DNA clones. Nature. 1984;312:330–337.CrossRefPubMedGoogle Scholar
  3. 3.
    Schwartz RS, Abildgaard CF, Aledort LM, et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A: Recombinant Factor VIII Study Group. N Engl J Med. 1990;323:1800–1805.CrossRefPubMedGoogle Scholar
  4. 4.
    Yoshioka A. Advances in hemophilia and other coagulation disorders: recombinant factor VIII preparations. Int J Pediatr Hematol Oncol. 1994;1:491–497.Google Scholar
  5. 5.
    Fukui H,Yoshioka A, Shima M, et al. Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A. Int J Hematol. 1991;54:419–427.PubMedGoogle Scholar
  6. 6.
    Fukui H, Mori K, Ishikawa M, et al. A long-term, multicenter clinical study of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A [in Japanese]. Nihon Yuketsu Gakkai Zasshi. 1991;37:593–604.Google Scholar
  7. 7.
    Yoshioka A, Fukutake K, Takamatsu J, et al. Clinical evaluation of a recombinant factor VIII preparation (Kogenate) in previously untreated patients with hemophilia A. Int J Hematol. 2003;78:467–474.CrossRefPubMedGoogle Scholar
  8. 8.
    Kasper CK, Aledort LM, Counts RB, et al. A more uniform measurement of factor VIII inhibitors [letter]. Thromb Diath Haemorrh. 1975;34:869–872.Google Scholar
  9. 9.
    Shima M, Sawamoto Y, Nakai H, et al. Measurement of anti-factor VIII IgG, IgG4 and IgM alloantibodies in previously untreated hemophilia A patients treated with recombinant factor VIII: Kogenate Japanese Clinical Study Group. Int J Hematol. 1995;62:35–43.CrossRefPubMedGoogle Scholar
  10. 10.
    Ehrenforth S, Kruetz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet. 1992;339:594–598.CrossRefPubMedGoogle Scholar
  11. 11.
    Addiego J, Kasper C, Abildgaard C, et al. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet. 1993;342:462–464.CrossRefPubMedGoogle Scholar
  12. 12.
    Ljung R, Petrini P, Lindgren A, et al. Factor VIII and factor IX inhibitor in haemophiliacs. Lancet. 1992;339:1550–1551.CrossRefPubMedGoogle Scholar
  13. 13.
    deBiasi R, Rocino A, Papa ML, et al. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates. Thromb Haemost. 1994;71:544–547.Google Scholar
  14. 14.
    Schwartz RS, Abildgaard CF, Aledort LM, et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of haemophilia A. N Engl J Med. 1990;323:1800–1805.CrossRefPubMedGoogle Scholar
  15. 15.
    Bray GL, Gomperts ED, Courter S, et al. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy and inhibitor risk in previously untreated individuals with hemophilia A. Blood. 1994;83:2428–2435.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Lusher JM, Spira J, Rodriguez D. A four-year update of safety and efficacy of an albumin-free formulated B-domain deleted factor VIII (BDD rFVIII, rVIIISQ) in previously untreated severe hemophilia A patients. Thromb Haemost. 1999;82:1493.Google Scholar
  17. 17.
    Abe T, Igata A, Ikematsu S, et al. Multicenter clinical effect of heat-treated factor VIII (CP-8) preparation for patients with hemophilia A [in Japanese]. Rinshio to Kenkyu. 1985;62:3640–3659.Google Scholar
  18. 18.
    Fujimaki M, Tanaka A, Fukutake K, et al. Clinical evaluation of recombinant factor VIII (BL-160) in patients with hemophilia A [in Japanese]. Nihon Kessen Shiketsu Gakkaishi. 1993;4:179–188.CrossRefGoogle Scholar
  19. 19.
    Fujimaki M, Goto M, Miyazaki T, et al. Clinical study of FVIII concentrate highly purified by monoclonal antibodies to FVIII(RCG- 11) [in Japanese]. Kiso to Rinsho. 1992;26:299–319.Google Scholar
  20. 20.
    McMillan C, Shapiro S, Whitehurst D, et al. The natural history of factor VIII C inhibitors in patients with hemophilia A. A national cooperative study II. Observations on the initial development of factor VIII C inhibitors. Blood. 1988;71:344–348.PubMedGoogle Scholar
  21. 21.
    White GC, Courter S, Bray GL, et al. A multicenter study of recombinant factor VIII (RecombinateH) in previously treated patient with hemophilia A. Thromb Haemost. 1997;77:660–667.PubMedGoogle Scholar
  22. 22.
    Seremetis S, Lusher JM,Abildgaard CF, et al. Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. Haemophilia. 1999;5:9–16.CrossRefPubMedGoogle Scholar
  23. 23.
    Lusher JM, Lee CA, Kessler CM, Bedrosian CL, for the ReFacto Phase 3 Study Group. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia. 2003;9:38–49.CrossRefPubMedGoogle Scholar
  24. 24.
    Giles AR, Rivard GE, Teitel J, Walker I. Surveillance for factor VIII inhibitor development in the Canadian hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. Transfus Sci. 1998;19:139–48.CrossRefPubMedGoogle Scholar
  25. 25.
    Smith MP, Giangrande P, Pollman H, et al. A postmarketing surveillance study of safety and efficacy of Refacto (St. Louis-derived active substance) in patients with haemophilia. Haemophilia. 2005;11:444–451.CrossRefPubMedGoogle Scholar
  26. 26.
    Rosendaal FR, Nieuwenhuis HK, van den Berg HM, et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands. Blood. 1993;81:2180–2186.PubMedGoogle Scholar
  27. 27.
    Giles AR, Verbruggen B, Rivard GE, Teitel J, Walker I. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis. Thromb Haemost. 1998;79:872–875.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2006

Authors and Affiliations

  • A. Yoshioka
    • 1
  • K. Fukutake
    • 2
  • J. Takamatsu
    • 3
  • A. Shirahata
    • 4
  • Kogenate Post-Marketing Surveillance Study Group
  1. 1.Department of PediatricsNara Medical UniversityKashiharaJapan
  2. 2.Department of Clinical Laboratory MedicineTokyo Medical CollegeTokyoJapan
  3. 3.Department of Blood Transfusion, Internal Medicine INagoya University School of MedicineNagoya
  4. 4.Department of PediatricsUniversity of Occupational and Environmental Health, JapanKitakyushuJapan

Personalised recommendations